NeXendia Overview
- Status
-
Private
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
1
NeXendia General Information
Description
Developer of advanced diagnostic tools designed for non-invasive disease detection and monitoring. The company's platform utilizes extracellular RNA fragmentomics and cell-free RNA analysis in biofluids to provide real-time insights into tumor response and treatment toxicity, enabling pharmaceutical and hospital partners to improve patient stratification and accelerate oncology drug development through highly sensitive companion diagnostics.
Contact Information
Website
www.nexendia.comCorporate Office
- Zürich
- Switzerland
Corporate Office
- Zürich
- Switzerland
NeXendia Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Accelerator/Incubator | 25-Apr-2025 | Completed | Startup |
NeXendia Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Nucleate | Accelerator/Incubator |
NeXendia FAQs
-
Where is NeXendia headquartered?
NeXendia is headquartered in Zürich, Switzerland.
-
What industry is NeXendia in?
NeXendia’s primary industry is Laboratory Services (Healthcare).
-
Is NeXendia a private or public company?
NeXendia is a Private company.
-
What is NeXendia’s current revenue?
The current revenue for NeXendia is .
-
Who are NeXendia’s investors?
Nucleate has invested in NeXendia.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process